Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development

Fundamental and Clinical Pharmacology

Volumn 23, Issue 4, 2009, Pages 387-409

  Na Bangchang, Kesara ^a   Karbwang, Juntra ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Antimalarial drug; Drug research and development; Malaria; Pharmacology

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEETHER; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; CHLORCYCLOGUANIL; CHLOROQUINE; CHLORPROGUANIL; CHLORPROGUANIL PLUS DAPSONE; CLINDAMYCIN; DAPSONE; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; DIHYDROFOLATE REDUCTASE; FANSIDAR; FANSIMEF; HALOFANTRINE; MEFLOQUINE; PRIMAQUINE; PROGUANIL; PYRAMAX; PYRIMETHAMINE; PYRONARIDINE; QUININE; SULFADOXINE; TAFENOQUINE; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ANTIBIOTIC SENSITIVITY; ANTIBODY TITER; ANTIMALARIAL ACTIVITY; BIOINFORMATICS; BLINDNESS; BONE MARROW TOXICITY; BRAIN STEM INJURY; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CHEMOTHERAPY; CODON; COMBINATION CHEMOTHERAPY; COMBINATORIAL CHEMISTRY; CROSS RESISTANCE; DETOXIFICATION; DISEASE TRANSMISSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DESIGN; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME INHIBITION; ERYTHROCYTE; FUNDING; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; GENOMICS; HEARING IMPAIRMENT; HEART VENTRICLE ARRHYTHMIA; HIGH THROUGHPUT SCREENING; HOST PARASITE INTERACTION; HUMAN; HYPOGLYCEMIA; HYPOTENSION; IMMUNE RESPONSE; INFECTION PREVENTION; INTRAVASCULAR HEMOLYSIS; LIVER TOXICITY; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MICROARRAY ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORBIDITY; MORTALITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PARASITEMIA; PATIENT COMPLIANCE; PLASMA PROTEIN BINDING; PLASMODIUM (LIFE CYCLE STAGE); PLASMODIUM MALARIAE INFECTION; PLASMODIUM OVALE MALARIA; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEOMICS; PSYCHOSIS; QT PROLONGATION; RETINOPATHY; REVIEW; SEIZURE; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIMALARIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE; GENOME, PROTOZOAN; HUMANS; MALARIA; PLASMODIUM;

EID: 68749096275     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00709.x     Document Type: Review

References (228)

1. Na-Bangchang K., Congpuong K. Current malaria status and distribution of drug resistance in East and Southeast Asia with special focus to Thailand. Tohoku J. Exp. Med. (2007) 211 99 113.
2. Ringwald P. Current antimalarial drugs: resistance and new strategies. Bull. Acad. Natl. Med. (2007) 191 1273 1284.
3. Bruce-Chwatt L.J. Chemotherapy of malaria, World Health Organization, Geneva, 1986.
4. Shah I. Chloroquine resistant vivax malaria in an infant: a report from India. J Vector. Borne Dis. (2008) 45 176 177.
5. Tjitra E., Anstey N.M., Sugiarto P. et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. (2008) 17 128.
6. Guthmann J.P., Pittet A., Lesage A. et al. Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Trop. Med. Int. Health (2008) 13 91 98.
7. Wongsrichanalai C., Pickard A.L., Wernsdorfer W.H. Epidemiology of drug-resistant malaria. Lancet Infect Dis. (2002) 2 209 218.
8. Byarugaba D.K. Antimicrobial resistance in developing countries and responsible risk factors. Int. J. Antimicrob. Agents (2004) 24 105 110.
9. Laufer M.K., Djimdé A.A., Plowe C.V. Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am. J. Trop. Med. Hyg. (2007) 77 160 169.
10. Vestergaard L.S., Ringwald P. Responding to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment policies. Am. J. Trop. Med. Hyg. (2007) 77 153 159.
11. Noedl H., Wongsrichanalai C., Wernsdorfer W.H. Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol. (2003) 4 175 181.
12. World Health Organization. In vitro micro-test (mark ii) for the assessment of the response of Plasmodium falciparum to chloroquine, mefloquine, quinine, sulfadoxine/pyrimethamine and amodiaquine, WHO/MAP/87.2, Rev.1. WHO, Geneva, 1990.
13. Desjardins R.E., Canfield C.J., Haynes J.D., Chulay J.D. Quantitative assessment of anti- malarial activity in vitro by a semi-automated microdilution technique. Antimicrob. Agents Chemother. (1979) 16 710 718.
14. Makler M.T., Ries J.M., Williams J.A. et al. Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity. Am. J. Trop. Med. Hyg. (1993) 48 739 741.
15. Noedl H., Walther H.W., Robert S.M., Chansuda W. Histidine rich protein II, a novel approach to antimalarial drug susceptibility testing. Antimicrob. Agents Chemother. (2002) 46 1658 1664.
16. White N.J. The assessment of antimalarial drug efficacy. Trends Parasitol. (2002) 18 458 464.
17. Brockelman C.R., Tan-Ariya P., Bunnag D. Development of in vitro microtest for the assessment of Plasmodium vivax sensitivity to chloroquine. Southeast Asian J. Trop. Med. Public Health (1989) 20 41 47.
18. Russell B.M., Udomsangpetch R., Rieckmann K.H., Kotecka B.M., Coleman R.E., Sattabongkot J. Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic. Antimicrob. Agents Chemother. (2003) 1 170 173.
19. Tasanor O., Noedl H., Na-Bangchang K., Congpuong K., Sirichaisinthop J., Wernsdorfer W.H. An in vitro system for assessing the sensitivity of Plasmodium vivax to chloroquine. Acta Trop. (2002) 83 49 61. (Pubitemid 34607758)
20. Congpuong K., Na-Bangchang K., Thimasarn K., Tasanor U., Wernsdorfer W.H. Sensitivity of Plasmodium vivax to chloroquine in Sa Kaeo Province, Thailand. Acta Trop. (2002) 83 117 121. (Pubitemid 34671158)
21. Wilson P.E., Alker A.P., Meshnick S.R. Real-time PCR methods for monitoring antimalarial drug resistance. Trends Parasitol. (2005) 6 278 283.
22. World Health Organization (WHO). Antimalarial drug combination therapy: report of WHO technical consultation, WHO, Geneva, Switzerland, 2001.
23. Bacon D.J., Jambou R., Fandeur T. et al. World antimalarial resistance network (WARN) II: in vitro antimalarial drug susceptibility. Malar. J. (2007) 6 120.
24. Plowe C.V. Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. Curr. Top. Microbiol. Immunol. (2005) 295 55 79.
25. Schlitzer M. Antimalarial drugs - what is in use and what is in the pipeline. Arch. Pharm. (Weinheim) (2008) 341 149 163.
26. Bruce C.L.J., Black R.H., Draig J.C. Chemotherapy of malaria, WHO, Geneva, Switzerland, 1986.
27. Winstanley P.A. Chemotherapy for falciparum malaria: the armoury, the problems and the prospects. Parasitol. Today (2000) 4 146 153.
28. Cooper R.G., Magwere T. Chloroquine has not disappeared. Afr. Health Sci. (2007) 7 185 186.
29. Eriksen J., Mwankusye S., Mduma S. et al. Antimalarial resistance and DHFR/DHPS genotypes of Plasmodium falciparum three years after introduction of sulfadoxine-pyrimethamine and amodiaquine in rural Tanzania. Trans. R. Soc. Trop. Med. Hyg. (2007) 12 12 19.
30. Barnes K.I., Little F., Smith P.J., Evans A., Watkins W.M., White N.J. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. (2006) 80 582 596.
31. Alkadi H.O. Antimalarial drug toxicity: a review. Chemotherapy (2007) 53 385 391.
32. Karbwang J., Molunto P., Bunnag D., Harinasuta T. Plasma quinine levels in patients with falciparum malaria when given alone or in combination with tetracycline with or without primaquine. Southeast Asian J. Trop. Med. Public Health (1991) 22 72 76.
33. Bunnag D., Karbwang J., Na-Bangchang K., Thanavibul A., Chittamas S., Harinasuta T. Quinine-tetracycline for multidrug resistant falciparum malaria. Southeast Asian J. Trop. Med. Public Health (1996) 27 15 18.
34. Vaidya A.D., Pandita N., Godse C., Meshram M. Argemone mexicana and epidemic dropsy: phytopharmacology and putative sequelae and therapy. J. Assoc. Physicians India (2001) 49 1041 1042.
35. Looareesuwan S., Imwong M., Wilairatana P. Chlorproguanil-dapsone for malaria in Africa. Lancet (2004) 363 1838 1839.
36. Legrand E., Volney B., Meynard J.B., Esterre P., Mercereau-Puijalon O. Resistance to dihydroartemisinin. Emerg. Infect. Dis. (2007) 13 808 809.
37. Wongsrichanalai C., Meshnick S.R. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg. Infect. Dis. (2008) 5 716.
38. Noedl H., Se Y., Schaecher K., Smith B.L., Socheat D., Fukuda M.M. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. (2008) 359 2619 2620.
39. Hien T.T., Davis T.M., Chuong L.V. et al. Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob. Agents Chemother. (2004) 48 4234 4239.
40. Taylor T.E., Wills B.A., Courval J.M., Molyneux M.E. Intramuscular artemether vs intravenous quinine: an open, randomized trial in Malawian children with cerebral malaria. Trop. Med. Int. Health (1998) 3 3 8.
41. Day N., Dondorp A.M. The management of patients with severe malaria. Am. J. Trop. Med. Hyg. (2007) 77 29 35.
42. Mendis K., Sina B.J., Marchesini P., Carter R. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. (2001) 64 97 106.
43. Rodríguez-Morales A.J., Delgado L., Martínez N., Franco-Paredes C. Impact of imported malaria on the burden of disease in northeastern Venezuela. J. Travel Med. (2006) 13 15 20.
44. Vinetz J.M. Emerging chloroquine-resistant Plasmodium vivax (Benign Tertian) malaria: the need for alternative drug treatment. Clin. Infect. Dis. (2006) 42 1073 1074.
45. Vale N., Moreira R., Gomes P. Primaquine revisited six decades after its discovery. Eur. J. Med. Chem. (2008) 44 1 17.
46. Leslie T., Mayan I., Mohammed N. et al. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS ONE (2008) 8 2861.
47. Elmes N.J., Nasveld P.E., Kitchener S.J., Kocisko D.A., Edstein M.D. The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. Trans. R. Soc. Trop. Med. Hyg. (2008) 11 1095 1101.
48. Krudsood S., Tangpukdee N., Wilairatana P. et al. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. (2008) 5 736 740.
49. Nosten F., Price R.N. New antimalarials. A risk-benefit analysis. Drug Saf. (1995) 4 264 273.
50. Sirima S.B., Gansané A. Artesunate-amodiaquine for the treatment of uncomplicated malaria. Expert. Opin. Investig. Drugs (2007) 7 1079 1085.
51. Shanks G.D. Treatment of falciparum malaria in the age of drug resistance. J. Postgrad. Med. (2006) 4 277 280.
52. White N.J. Preventing antimalarial drug resistance through combinations. Drug Resist. Updat. (1998) 1 3 9.
53. Shanks G.D., Edstein M.D. Modern malaria chemoprophylaxis. Drugs (2005) 15 2091 2110.
54. Hastings I.M., Watkins W.M., White N.J. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos. Trans. R. Soc. Lond. B Biol. Sci. (2002) 1420 505 519.
55. Shanks G.D., Kain K.C., Keystone J.S. Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. Clin. Infect. Dis. (2001) 3 381 385.
56. Peters W., Robinson B.L. The chemotherapy of rodent malaria. LVIII. Drug combinations to impede the selection of drug resistance, Part. 2: The new generation - artemisinin or artesunate with long-acting blood schizontocides. Ann. Trop. Med. Parasitol. (2000) 1 23 35.
57. Ortelli F., Maxwell C.A., Curtis J., Watkins W.M. Studies on anti-folate antimalarials in east Africa. Parassitologia (1999) 41 313 314.
58. White N.J., Olliaro P. Artemisinin and derivatives in the treatment of uncomplicated malaria. Med. Trop. (Mars) (1998) 58 54 56.
59. Ohrt C., Watt G., Teja-Isavadharm P. et al. Pharmacokinetics of an extended-dose halofantrine regimen in patients with malaria and in healthy volunteers. Clin. Pharmacol. Ther. (1995) 57 525 532.
60. Hastings I.M., Watkins W.M., White N.J. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos. Trans. R. Soc. Lond. B Biol. Sci. (2002) 357 505 519.
61. Fidock D.A., Rosenthal P.J., Croft S.L., Brun R., Nwaka S. Antimalarial drug discovery: efficacy models for compound screening. Nat. Rev. Drug. Discov. (2004) 6 509 520.
62. German P.I., Aweeka F.T. Clinical pharmacology of artemisinin-based combination therapies. Clin. Pharmacokinet. (2008) 2 91 102.
63. Majori G. Combined antimalarial therapy using artemisinin. Parassitologia (2004) 46 85 87.
64. Davis T.M., Karunajeewa H.A., Ilett K.F. Artemisinin-based combination therapies for uncomplicated malaria. Med. J. (2006) 182 181 185.
65. Adjei G.O., Goka B.Q., Kurtzhals J.A. Neurotoxicity of artemisinin derivatives. Clin. Infect. Dis. (2006) 43 16 18.
66. Dellicour S., Hall S., Chandramohan D., Greenwood B. The safety of artemisinins during pregnancy: a pressing question. Malar. J. (2007) 14 6 15.
67. Crockett M., Kain K.C. Tafenoquine: a promising new antimalarial agent. Expert. Opin. Investig. Drugs (2007) 16 705 715.
68. Grellier P., Depoix D., Schrével J., Florent I. Discovery of new targets for antimalarial chemotherapy. Parasite (2008) 3 219 225.
69. Kurtzhals J. Clinical Pharmacology of Antimalarial Drugs - First AHRO International Malaria Symposium. IDrugs (2008) 10 713 715.
70. Winzeler E.A. Malaria research in the post-genomic era. Nature (2008) 455 751 756.
71. Cooper R.A., Carucci D.J. Proteomic approaches to studying drug targets and resistance in Plasmodium. Curr. Drug. Targets Infect. Disord. (2004) 1 41 51.
72. Basilico N., Bosisio E., Buelli F. et al. Old and new targets for innovative antimalarial compounds: the different strategies of the Italian malaria network. Parassitologia (2008) 50 133 136.
73. Felger I., Beck H.P. Fitness costs of resistance to antimalarial drugs. Trends Parasitol. (2008) 8 331 333.
74. Krishna S., White N.J. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin. Pharmacokinet. (1996) 30 263 299.
75. White N.J., Looareesuwan S., Warrell D.A., Warrell M.J., Bunnag D., Harinasuta T. Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. Am. J. Med. (1982) 73 564 572.
76. White N.J. Clinical pharmacokinetics of antimalarial drugs. Clin. Pharmacokinet. (1985) 10 187 215.
77. Silamut K., White N.J., Looareesuwan S., Warrell D.A. Binding of quinine to plasma proteins in falciparum malaria. Am. J. Trop. Med. Hyg. (1985) 34 681 686. (Pubitemid 16237009)
78. Krishna S., Nagaraja N.V., Planche T. et al. Population pharmacokinetics of intramuscular quinine in children with severe malaria. Antimicrob. Agents Chemother. (2001) 45 1803 1809.
79. Ducharme J., Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin. Pharmacokinet. (1996) 31 257 274.
80. O'Neill P.M., Stocks P.A., Pugh M.D. et al. Design and synthesis of endoperoxide antimalarial prodrug models. Angew. Chem. Int. Ed. Engl. (2004) 43 4193 4197.
81. Helsby N.A., Ward S.A., Edwards G., Howells R.E., Breckenridge A.M. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br. J. Clin. Pharmacol. (1990) 30 593 598. (Pubitemid 20346486)
82. Skjelbo E., Mutabingwa T.K., Bygbjerg I., Nielsen K.K., Gram L.F., Brøosen K. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin. Pharmacol. Ther. (1996) 59 304 311.
83. Watkins W.M., Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans. R. Soc. Trop. Med. Hyg. (1993) 87 75 78.
84. Palmer K.J., Holliday S.M., Brogden R.N. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1993) 45 430 475.
85. Karbwang J., Na Bangchang K., Bunnag D., Harinasuta T., Laothavorn P. Cardiac effect of halofantrine. Lancet (1993) 342 501 509.
86. Navaratnam V., Mansor S.M., Sit N.W., Grace J., Li Q., Olliaro P. Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet. (2000) 39 255 270.
87. Berman J. Toxicity of commonly-used antimalarial drugs. Travel Med. Infect. Dis. (2004) 2 171 184.
88. Brewer T.G., Peggins J.O., Grate S.J. et al. Neurotoxicity in animals due to arteether and artemether. Trans. R. Soc. Trop. Med. Hyg. (1994) 88 S33 S36.
89. Brewer T.G., Grate S.J., Peggins J.O. et al. Fatal neurotoxicity of arteether and artemether. Am. J. Trop. Med. Hyg. (1994) 51 251 259.
90. Kamchonwongpaisan S., McKeever P., Hossler P., Ziffer H., Meshnick S.R. Artemisinin neurotoxicity: neuropathology in rats and mechanistic studies in vitro. Am. J. Trop. Med. Hyg. (1997) 56 7 12.
91. Petras J.M., Kyle D.E., Gettayacamin M. et al. Arteether: risks of two-week administration in Macaca mulatta. Am. J. Trop. Med. Hyg. (1997) 56 390 396.
92. Genovese R.F., Newman D.B., Li Q., Peggins J.O., Brewer T.G. Dose-dependent brainstem neuropathology following repeated arteether administration in rats. Brain Res. Bull. (1998) 45 199 202.
93. Petras J.M., Young G.D., Bauman R.A. Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: the lateral reticular nuclei, paramedian reticular nuclei, and perihypoglossal nuclei. Anat. Embryol. (Berl) (2000) 201 383 397.
94. Panosian C.B. Economic access to effective drugs for falciparum malaria. Clin. Infect. Dis. (2005) 40 713 717.
95. Kager P.A., Schultz M.J., Zijlstra E.E., van den Berg B., van Boxtel C.J. Arteether administration in humans: preliminary studies of pharmacokinetics, safety and tolerance. Trans. R. Soc. Trop. Med. Hyg. (1994) 88 S53 S54.
96. Toovey S., Jamieson A. Response to: artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol. Lett. (2004) 151 489 490.
97. Toovey S. Safety of artemisinin antimalarials. Clin. Infect. Dis. (2006) 42 1214 1215.
98. Miller L.G., Panosian C.B. Ataxia and slurred speech after artesunate treatment for falciparum malaria. N. Engl. J. Med. (1997) 336 1328.
99. Elias Z., Bonnet E., Marchou B., Massip P. Neurotoxicity of artemisinin: possible counseling and treatment of side effects. Clin. Infect. Dis. (1999) 28 1330 1331.
100. Franco-Paredes C., Dismukes R., Nicolls D., Kozarsky P.E. Neurotoxicity due to antimalarial therapy associated with misdiagnosis of malaria. Clin. Infect. Dis. (2005) 40 1710 1711.
101. van Hensbroek M.B., Onyiorah E., Jaffar S. et al. A trial of artemether or quinine in children with cerebral malaria. N. Engl. J. Med. (1996) 335 69 75.
102. White N.J., Ashley E.A., Nosten F. Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Ann. Neurol. (2006) 59 725 726.
103. Ringwald P. Current antimalarial drugs: resistance and new strategies. Bull. Acad. Natl. Med. (2007) 7 1273 1284.
104. Patel A.P., Staines H.M., Krishna S. New antimalarial targets: the example of glucose transport. Travel Med. Infect. Dis. (2008) 6 58 66.
105. Sahu N.K., Sahu S., Kohli D.V. Novel molecular targets for antimalarial drug development. Chem. Biol. Drug. Des. (2008) 4 287 297.
106. Barnes K.I., Watkins W.M., White N.J. Antimalarial dosing regimens and drug resistance. Trends Parasitol. (2008) 3 127 134.
107. Lanteri C.A., Johnson J.D., Waters N.C. Recent advances in malaria drug discovery. Recent Pat. Antiinfect. Drug. Discov. (2007) 2 95 114.
108. Egan T.J., Kaschula C.H. Strategies to reverse drug resistance in malaria. Curr. Opin. Infect. Dis. (2007) 6 598 604.
109. Arav-Boger R., Shapiro T.A. Molecular mechanisms of resistance in antimalarial chemotherapy: the unmet challenge. Annu. Rev. Pharmacol. Toxicol. (2005) 45 565 585.
110. Ekland E.H., Fidock D.A. Advances in understanding the genetic basis of antimalarial drug resistance. Curr. Opin. Microbiol. (2007) 10 363 370.
111. Djimdé A., Doumbo O.K., Steketee R.W., Plowe C.V. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. (2001) 344 257 263.
112. Uhlemann A.C., Krishna S. Antimalarial multi-drug resistance in Asia: mechanisms and assessment. Curr. Top. Microbiol. Immunol. (2005) 295 39 53.
113. Uhlemann A.C., Cameron A., Eckstein-Ludwig U. et al. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat. Struct. Mol. Biol. (2005) 12 628 629.
114. Yuvaniyama J., Chitnumsub P., Kamchonwongpaisan S. et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nat. Struct. Biol. (2003) 10 357 365.
115. Yuthavong Y., Yuvaniyama J., Chitnumsub P. et al. Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors. Parasitology (2005) 130 249 259.
116. Meshnick S.R. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. (2002) 32 1655 1660.
117. Bray P.G., Ward S.A., O'Neill P.M. Quinolines and artemisinin: chemistry, biology and history. Curr. Top. Microbiol. Immunol. (2005) 295 3 38.
118. Hawkins V.N., Joshi H., Rungsihirunrat K., Na-Bangchang K., Sibley C.H. Antifolates can have a role in the treatment of Plasmodium vivax. Trends Parasitol. (2007) 23 213 222.
119. Rungsihirunrat K., Na-Bangchang K., Hawkins V.N., Mungthin M., Sibley C.H. Sensitivity to antifolates and genetic analysis of Plasmodium vivax isolates from Thailand. Am. J. Trop. Med. Hyg. (2007) 76 1057 1065.
120. Bray P.G., Mungthin M., Hastings I.M. et al. PfCRT and the trans-vascular proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. Mol. Microbiol. (2006) 62 238 251.
121. Foley M., Tilley L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol. Ther. (1998) 79 55 87.
122. O'Neill P.M., Bray P.G., Hawley S.R., Ward S.A., Park B.K. 4-Aminoquinolines-past, present, and future: a chemical perspective. Pharmacol. Ther. 1998) 77 29 58.
123. Ginsburg I., Sadovnik M., Sallon S. et al. PADMA-28, a traditional tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids. Inflamnopharmacology (1999) 7 47 62.
124. Bonilla J.A., Bonilla T.D., Yowell C.A., Fujioka H., Dame J.B. Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function. Mol. Microbiol. (2007) 65 64 75.
125. Fidock D.A., Nomura T., Talley A.K. et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell (2000) 6 861 871.
126. Graves P.R., Kwiek J.J., Fadden P. et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. (2002) 62 1364 1372.
127. Asawamahasakda W., Benakis A., Meshnick S.R. The interaction of artemisinin with red cell membranes. J. Lab. Clin. Med. (1994) 123 757 762.
128. Bhisutthibhan J., Pan X.Q., Hossler P.A. et al. The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin. Biol. Chem. (1998) 273 16192 16198.
129. Eckstein-Ludwig U., Webb R.J., Van Goethem I.D. et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature (2003) 424 957 961.
130. Mercereau-Puijalon O., Fandeur T. Antimalarial activity of artemisinins: identification of a novel target? Lancet (2003) 362 2035 2036.
131. Wang J.X., Tang W., Shi L.P. et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br. J. Pharmacol. (2007) 150 652 661.
132. Biagini G.A., O'Neill P.M., Nzila A., Ward S.A., Bray P.G. Antimalarial chemotherapy: young guns or back to the future? Trends Parasitol. (2003) 19 479 487.
133. Biot C., Chibale K. Novel approaches to antimalarial drug discovery. Infect. Disord. Drug Targets (2006) 6 173 204.
134. Yeh I., Altman R.B. Drug Targets for Plasmodium falciparum: a post-genomic eview/survey. Mini. Rev. Med. Chem. (2006) 6 177 202.
135. Birkholtz L., van Brummelen A.C., Clark K. et al. Exploring functional genomics for drug target and therapeutics discovery in Plasmodia. Acta Trop. (2008) 105 113 123.
136. Bhattacharjee A.K., Nichols D.A., Gerena L., Roncal N., Gutteridge C.E. An in silico 3D pharmacophore model of chalcones useful in the design of novel antimalarial agents. Med. Chem. (2007) 3 317 326.
137. Mehlin C. Structure-based drug discovery for Plasmodium falciparum. Comb. Chem. High Throughput Screen. (2005) 8 5 14.
138. Yanow S.K., Purcell L.A., Lee M., Spithill T.W. Genomics-based drug design targets the AT-rich malaria parasite: implications for antiparasite chemotherapy. Pharmacogenomics (2007) 8 1267 1272.
139. Woynarowski J.M., Krugliak M., Ginsburg H. Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs. Mol. Biochem. Parasitol. (2007) 154 70 81.
140. Liñares G.E., Rodriguez J.B. Current status and progresses made in malaria chemotherapy. Curr. Med. Chem. (2007) 14 289 314.
141. Padmanaban G., Nagaraj V.A., Rangarajan P.N. An alternative model for heme biosynthesis in the malarial parasite. Trends Biochem. Sci. (2007) 32 443 449.
142. Choi S.R., Mukherjee P., Avery M.A. The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr. Med. Chem. (2008) 15 161 171.
143. Jana S., Paliwal J. Novel molecular targets for antimalarial chemotherapy. Int. J. Antimicrob. Agents (2007) 30 4 10.
144. Ersmark K., Samuelsson B., Hallberg A. Plasmepsins as potential targets for new antimalarial therapy. Med. Res. Rev. (2006) 26 626 666.
145. Rathore D. Targeting parasite-mediated host hemoglobin degradation in malaria. Drugs (2007) 10 877 880.
146. Auparakkitanon S., Chapoomram S., Kuaha K., Chirachariyavej T., Wilairat P. Targeting of hematin by the antimalarial pyronaridine. Antimicrob. Agents Chemother. (2006) 50 2197 2200.
147. Mi-Ichi F., Miyadera H., Kobayashi T. et al. Parasite mitochondria as a target of chemotherapy: inhibitory effect of licochalcone A on the Plasmodium falciparum respiratory chain. Ann. N Y Acad. Sci. (2005) 1056 46 54.
148. Köhler S., Delwiche C.F., Denny P.W. et al. A plastid of probable green algal origin in apicomplexan parasites. Science (1997) 275 1485 1489.
149. Ralph S.A., D'Ombrain M.C., McFadden G.I. The apicoplast as an antimalarial drug target. Drug Resist. Updat. (2001) 4 145 151.
150. Roos D.S., Crawford M.J., Donald R.G. et al. Mining the Plasmodium genome database to define organellar function: what does the apicoplast do? Philos. Trans. R. Soc. Lond B. Biol. Sci. (2002) 357 35 46.
151. Rohdich F., Bacher A., Eisenreich W. Isoprenoid biosynthetic pathways as anti-infective drug targets. Biochem. Soc. Trans. (2005) 33 785 791.
152. Jomaa H., Wiesner J., Sanderbrand S. et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science (1999) 285 1573 1576.
153. Lu J.Z., Lee P.J., Waters N.C., Prigge S.T. Fatty Acid synthesis as a target for antimalarial drug discovery. Comb. Chem. High Throughput Screen. (2005) 8 15 26.
154. Tasdemir D., Lack G., Brun R. et al. Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J. Med. Chem. (2006) 49 3345 3353.
155. Gelb M.H., Van Voorhis W.C., Buckner F.S. et al. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol. Biochem. Parasitol. (2003) 126 155 163.
156. Nallan L., Bauer K.D., Bendale P. et al. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J. Med. Chem. (2005) 48 3704 3713.
157. Reddy D.M. Comparative protein modeling of spermidine synthase from Plasmodium falciparum: A potential target for anti-malarial drug therapy. Bioinformation (2006) 23 310 313.
158. Doerig C., Meijer L. Antimalarial drug discovery: targeting protein kinases. Expert. Opin. Ther. Targets (2007) 11 279 290.
159. Chan M., Tan D.S., Wong S.H., Sim T.S. A relevant in vitro eukaryotic live-cell system for the evaluation of plasmodial protein localization. Biochimie (2006) 88 1367 1375.
160. Tuteja R. Helicases - feasible antimalarial drug target for Plasmodium falciparum. FEBS J. (2007) 274 4699 4704.
161. Gero A.M., O'Sullivan W.J. Purines and pyrimidines in malarial parasites. Blood Cells (1999) 16 467 484.
162. Hassans H.F., Coombs G.H. Purine and pyrimidine metabolism in parasite protozoa. FEMSM Microbiol. Rev. (1988) 4 47 83.
163. Baldwin S.A., McConkey G.A., Cass C.E., Young J.D. Nucleoside transport as a potential target for chemotherapy in malaria. Curr. Pharm. Des. (2007) 13 569 580.
164. Krungkrai S.R., DelFraino B.J., Smiley J.A. et al. A novel enzyme complex of orotate phosphoribosyltransferase and orotidine 5′-monophosphate decarboxylase in human malaria parasite Plasmodium falciparum: physical association, kinetics, and inhibition characterization. Biochemistry (2005) 44 1643 1652.
165. Yuthavong Y., Kamchonwongpaisan S., Leartsakulpanich U., Chitnumsub P. Folate metabolism as a source of molecular targets for antimalarials. Future Microbiol. (2006) 1 113 125.
166. Azarova A.M., Lyu Y.L., Lin C.P. et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA (2007) 104 11014 11019.
167. Sherman I.W. Biochemistry of Plasmodium (malarial parasite). Microbiol. Rev. (1979) 43 453 495.
168. Dunn C.R., Banfield M.J., Barker J.J. et al. The structure of lactate dehydrogenase from Plasmodium falciparum reveals a new target for antimalrial design. Narure Struct. Biol. (1996) 3 17 20.
169. Kirk K., Saliba K.J. Targeting nutrient uptake mechanisms in Plasmodium. Curr. Drug Targets (2007) 8 75 88.
170. Staines H.M., Ellory J.C., Chibale K. The new permeability pathways: targets and selective routes for the development of new antimalarial agents. Comb. Chem. High Throughput Screen. (2005) 8 81 88.
171. Rahlfs S., Becker K. Interference with redox-active enzymes as a basis for the design of antimalarial drugs. Mini. Rev. Med. Chem. (2006) 6 163 176.
172. Ahmad R., Srivastava A.K. Purification and biochemical characterization of cytosolic glutathione-S-transferase from malarial parasites Plasmodium yoelii. Parasitol. Res. (2007) 100 581 588.
173. Friebolin W., Jannack B., Wenzel N. et al. Antimalarial dual drugs based on potent inhibitors of glutathione reductase from Plasmodium falciparum. J. Med. Chem. (2008) 51 1260 1277.
174. Pankova-Kholmyansky I., Flescher E. Potential new antimalarial chemotherapeutics based on sphingolipid metabolism. Chemotherapy (2006) 52 205 209.
175. Golenser J., Waknine J.H., Krugliak M., Hunt N.H., Grau G.E. Current perspectives on the mechanism of action of artemisinins. Int. J. Parasitol. (2006) 36 1427 1441.
176. Kappes B., Rohrbach P. Microtubule inhibitors as a potential treatment for malaria. Future Microbiol. (2007) 2 409 423.
177. Rawat D.S., Lumb V., Sharma Y.D., Pasha S.T., Singh G. Histone as future drug target for malaria. J. Commun. Dis. (2007) 39 119 128.
178. Shenai B.R., Semenov A.V., Rosenthal P.J. Stage-specific antimalarial activity of cysteine protease inhibitors. Biol. Chem. (2002) 383 843 847.
179. Bjelic S., Nervall M., Gutiérrez-de-Terán H., Ersmark K., Hallberg A., Aqvist J. Computational inhibitor design against malaria plasmepsins. Cell. Mol. Life Sci. (2007) 64 2285 2305.
180. Sharma A. Malarial protease inhibitors: potential new chemotherapeutic agents. Curr. Opin. Investig. Drugs (2007) 8 642 652.
181. Shenai B.R., Rosenthal P.J. Reducing requirements for hemoglobin hydrolysis by Plasmodium falciparum cysteine proteases. Mol. Biochem. Parasitol. (2002) 122 99 104.
182. Karunajeewa H.A., Manning L., Mueller I., Ilett K.F., Davis T.M. Rectal administration of artemisinin drivatives for the treatment of malaria. JAMA (2007) 297 2381 2390.
183. Martinelli A., Moreira R., Ravo P.V. Malaria combination therapies: advantages and shortcomings. Mini. Rev. Med. Chem. (2008) 8 201 212.
184. Aweeka F.T., German P.I. Clinical pharmacology of artemisinin-based combination therapies. Clin. Pharmacokinet. (2008) 47 91 102.
185. Mutabingwa T.K. Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy! Acta Trop. (2005) 95 305 315.
186. Nosten F., White N.J. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. (2007) 77 181 192.
187. Lefèvre G., Looareesuwan S., Treeprasertsuk S. et al. clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. (2001) 64 247 256.
188. Mutabingwa T., Nzila A., Mberu E. et al. hlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet (2001) 358 1218 1223.
189. Wootton D.G., Opara H., Biagini G.A. et al. Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria. PLoS ONE (2008) 5 1779.
190. Shao B.R. A review of antimalarial drug pyronaridine. Chin. Med. J. (Engl) (1990) 103 428 434.
191. Edwards G., Biagini G.A. Resisting resistance: dealing with the irrepressible problem of malaria. Br. J. Clin. Pharmacol. (2006) 61 690 693.
192. Ramharter M., Kurth F., Schreier A.C. et al. Fixed-Dose Pyronaridine-Artesunate Combination for Treatment of Uncomplicated Falciparum Malaria in Pediatric Patients in Gabon. J. Infect. Dis. (2008) 198 911 919.
193. Giao P.T., de Vries P.J., Hung le Q., Binh T.Q., Nam N.V., Kager P.A. CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam. Trop. Med. Int. Health (2004) 9 209 216.
194. Karema C., Fanello C.I., van Overmeir C. et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans. R. Soc. Trop. Med. Hyg. (2006) 100 1105 1111. (Pubitemid 44464010)
195. Davis T.M., Hung T.Y., Sim I.K., Karunajeewa H.A., Ilett K.F. iperaquine: a resurgent antimalarial drug. Drugs (2005) 65 75 87.
196. Yang H.L., Yang P.F., Liu D.Q. et al. ensitivity in vitro of Plasmodium falciparum to chloroquine, pyronaridine, artesunate and piperaquine in south Yunnan. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (1992) 10 198 200.
197. Hung T.Y., Davis T.M., Ilett K.F. et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. (2004) 57 253 262.
198. Adjei G.O., Kurtzhals J.A., Rodrigues O.P. et al. Amodiaquine-artesunate vs artemether-lumefantrine or uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar. J. (2008) 7 127 138.
199. Krogstad D.J., Pearson R.D., Bennett J.E., Dolin R., Mandell G.L. Dosage for malaria treatment. Lancet (1996) 348 1311 1312.
200. Mzayek F., Deng H., Mather F.J. et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin. Trials (2007) 2 6.
201. Madrid P.B., Wilson N.T., DeRisi J.L., Guy R.K. Parallel synthesis and antimalarial screening of a 4-aminoquinoline library. J. Comb. Chem. (2004) 6 437 442.
202. Anderson M.O., Sherrill J., Madrid P.B. et al. Parallel synthesis of 9-aminoacridines and their evaluation against chloroquine-resistant Plasmodium falciparum. Bioorg. Med. Chem. (2006) 14 334 343.
203. Davis C.B., Bambal R., Moorthy G.S. et al. Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials. J. Pharm. Sci. (2008) 18 362 337.
204. Casagrande M., Basilico N., Parapini S., Romeo S., Taramelli D., Sparatore A. Novel amodiaquine congeners as potent antimalarial agents. Bioorg. Med. Chem. (2008) 16 6813 6823.
205. O'Neill P.M., Mukhtar A., Stocks P.A. et al. soquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. J. Med. Chem. (2003) 46 4933 4945.
206. Tekwani B.L., Walker L.A. 8-Aminoquinolines: future role as antiprotozoal drugs. Curr. Opin. Infect Dis. (2006) 19 623 631.
207. Kinyanjui S.M., Mberu E.K., Winstanley P.A., Jacobus D.P., Watkins W.M. The antimalarial triazine WR99210 and the prodrug PS-15: folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug. Am. J. Trop. Med. Hyg. (1999) 60 943 947.
208. Hastings M.D., Sibley C.H. Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. Proc. Natl. Acad. Sci. USA (2002) 99 13.
209. Jefford C.W. Why artemisinin and certain synthetic peroxides are potent antimalarials. Implications for the mode of action. Curr. Med. Chem. (2001) 8 1803 1826.
210. Haynes R.K. From artemisinin to new artemisinin antimalarials: biosynthesis, extraction, old and new derivatives, stereochemistry and medicinal chemistry requirements. Curr. Top. Med. Chem. (2006) 6 509 537.
211. Vivas L., Rattray L., Stewart L. et al. Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo. J. Antimicrob. Chemother. (2007) 59 658 665.
212. Vennerstrom J.L., Arbe-Barnes S., Brun R. et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature (2004) 430 900 904.
213. Basso L.A., da Silva L.H., Fett-Neto A.G. et al. The use of biodiversity as source of new chemical entities against defined molecular targets for treatment of malaria, tuberculosis, and T-cell mediated diseases. Mem. Inst. Oswaldo Cruz (2005) 100 475 506.
214. Phillipson J.D. Natural products as drugs. Trans. R. Soc. Trop. Med. Hyg. (1994) 88 17 19.
215. Le Tran Q., Le Tran Y., Tezuka Y. et al. In vitro antiplasmodial activity of antimalarial medicinal plants used in Vietnamese traditional medicine. J. Ethnopharmacol. (2003) 86 249 252.
216. Wanyoike G.N., Chhabra S.C., Lang'at-Thoruwa C.C., Omar S.A. Brine shrimp toxicity and antiplasmodial activity of five Kenyan medicinal plants. J. Ethnopharmacol. (2004) 90 129 133.
217. Brandao T.S.M., Grandi E.M.M., Rocha D.R. et al. Survey of medicinal plants used as antimalarials in the Amazon. J. Ethnopharmacol. (1994) 36 175 182.
218. Andrade-Neto V.F., Brandão M.G., Stehmann J.R., Oliveira L.A., Krettli A.U. Antimalarial activity of Cinchona-like plants used to treat fever and malaria in Brazil. J. Ethnopharmacol. (2003) 87 253 256.
219. Wright C.W. Traditional antimalarials and the development of novel antimalarial drugs. J. Ethnopharmacol. (2005) 100 67 71.
220. Dann O., Fick H., Pietzner B. et al. Trypanocidal diamidine with three isolated ring systems. Justus Liebigs Ann. Chem. (1975) 1 160 194.
221. Das B.P., Boykin D.W. Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. J. Med. Chem. (1997) 20 531 536.
222. Yeramian P., Meshnick S.R., Krudsood S. et al. Efficacy of DB289 in Thai patients with Plasmodium vivax or acute, uncomplicated Plasmodium falciparum infections. J. Infect. Dis. (2005) 192 319 322.
223. Lanteri C.A., Trumpower B.L., Tidwell R.R., Meshnick S.R. DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. (2004) 48 3968 3974.
224. Stead A.M., Bray P.G., Edwards I.G. et al. Diamidine compounds: selective uptake and targeting in Plasmodium falciparum. Mol. Pharmacol. (2001) 59 1298 1306.
225. Biagini G.A., Ward S.A., Bray P.G. Malaria parasite transporters as a drug-delivery strategy. Trends Parasitol. (2005) 21 299 301.
226. Egan T.J., Kaschula C.H. Strategies to reverse drug resistance in malaria. Curr. Opin. Infect Dis. (2007) 20 598 604.
227. van Schalkwyk D.A., Egan T.J. Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum. Drug Resist. Updat. (2006) 9 211 226.
228. Taylor D., Walden J.C., Robins A.H., Smith P.J. Role of the neurotransmitter reuptake-blocking activity of antidepressants in reversing chloroquine resistance in vitro in Plasmodium falciparum. Antimicrob. Agents Chemother. (2000) 44 2689 2692.